This article is provided for educational and informational purposes only. All compounds discussed are supplied strictly for laboratory and research use. Vitro Labs products are not for human or animal consumption.
Ipamorelin is one of the cleanest molecules in growth hormone research. That’s not marketing language. It’s a pharmacological description that traces back to a specific 1998 paper by Kirsten Raun and her team at Novo Nordisk in Copenhagen, who reported that a newly synthesized 5-amino-acid compound. five amino acids in a tidy ring-and-tail structure. could trigger pulsatile growth hormone release in rats and swine without simultaneously spiking cortisol, prolactin, or ACTH (PMID: 9849822).
That selectivity is the whole story. It’s why ipamorelin became a reference compound in growth hormone secretagogue research for the next two decades. It’s why nearly every comparison paper in the GHRP family. GHRP-2, GHRP-6, hexarelin, ghrelin itself. uses ipamorelin as the clean control. And it’s why ipamorelin still shows up in laboratory protocols today, often paired with a GHRH analog like CJC-1295 to study the two-receptor synergy that defines pulsatile GH biology.
This guide reviews ipamorelin’s structure, mechanism, key research findings, comparison context, handling considerations, and where the 2026 literature stands. for laboratory research use only.
Before the deep dive, here’s the short version of what the published literature reports about ipamorelin:
Ipamorelin is a synthetic 5-amino-acid compound. a string of five modified amino acids. developed at Novo Nordisk in the late 1990s as part of a structured search for a clean growth hormone secretagogue. The compound was first described in detail by Raun and colleagues in a 1998 paper in the European Journal of Endocrinology (PMID: 9849822), and it built on a family of earlier compounds (GHRP-6, GHRP-2, hexarelin) that all triggered GH release but with messy side-receptor activity.
The structure itself reads like a small chemistry puzzle: Aib (alpha-aminoisobutyric acid) at the front, then histidine, then two D-amino acids (D-2-naphthylalanine and D-phenylalanine), then a C-terminal lysine amide. The D-form amino acids and the amide cap aren’t decorative. They’re protective. They slow enzymatic degradation, which is why a compound this small still has a roughly 2-hour half-life in research models instead of being chewed up in minutes.
Pharmacologically, ipamorelin belongs to the GHRP class. growth hormone releasing compounds. These compounds are sometimes called ghrelin mimetics, because they bind and activate the same receptor (GHSR-1a) that the body’s natural hunger and GH-releasing hormone, ghrelin, binds. But ipamorelin is not a copy of ghrelin. It’s a small, structurally distinct molecule that happens to fit the same receptor lock.
Growth hormone biology is pulsatile. The pituitary doesn’t release GH in a steady drip. it releases it in bursts, primarily at night, controlled by two upstream signals: growth hormone releasing hormone (GHRH) from the hypothalamus, which says “release more,” and somatostatin, which says “hold.” Ghrelin and synthetic ghrelin mimetics like ipamorelin add a third input. They bind GHSR-1a on pituitary somatotroph cells and on hypothalamic neurons, amplifying GH release on top of the GHRH signal.
At the receptor level, GHSR-1a is a G-protein-coupled receptor. When ipamorelin binds, the receptor activates the Gq pathway, which triggers phospholipase C, which generates inositol trisphosphate, which releases intracellular calcium. and that calcium release is what physically pushes GH-containing vesicles out of the somatotroph cell. The cascade was mapped across multiple groups in the late 1990s and 2000s.
The cleaner the receptor binding, the cleaner the experimental readout. For investigators studying GH biology. pulsatility, downstream IGF-1 dynamics, tissue-level effects of GH signaling. confounding hormonal noise is the central methodological problem. A compound that triggers GH cleanly, without simultaneously activating the HPA axis or prolactin pathways, gives researchers a far cleaner experimental signal than the older GHRP-6 or hexarelin compounds, which produced significant cortisol and prolactin elevation alongside the GH response (Raun et al., 1998, PMID: 9849822).
The 1998 Raun paper is worth understanding in detail because it set the framing for everything that came after. The team ran head-to-head comparisons in rats and swine: ipamorelin versus GHRP-6 versus growth hormone releasing compound hexarelin versus saline control. They measured not just GH release, but also adrenocorticotropic hormone (ACTH), cortisol, and prolactin. the three off-target hormones that the older GHRPs were known to elevate.
The result: ipamorelin produced GH release comparable to GHRP-6 in magnitude, but the ACTH and cortisol responses were essentially flat. Prolactin was similarly unaffected. This was the first compound in the class to show that GHSR-1a activation could be uncoupled from the broader stress-axis response that contaminated the older molecules (PMID: 9849822).
“Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.”
, Raun et al. (1998), European Journal of Endocrinology, PMID: 9849822
That line. “selectivity for GH release similar to that displayed by GHRH”. is the reason ipamorelin became a reference compound. GHRH is the body’s native, specific GH-releasing signal. Saying a GHRP-receptor compound matches GHRH in selectivity means the compound activates one receptor and one downstream effect, without the noise.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. Ipamorelin is a research compound not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
The Raun paper is the citation everything else in the ipamorelin literature points back to. Conducted at Novo Nordisk’s Måløv research site, the team synthesized ipamorelin and ran the comparison protocol described above. They reported a GH release profile matching GHRP-6 in magnitude with the selectivity profile matching GHRH. the key finding that established ipamorelin’s research identity (PMID: 9849822). Published in the European Journal of Endocrinology.
Two follow-up studies extended the receptor pharmacology. Johansen and colleagues at Novo Nordisk characterized binding affinity at the cloned GHSR receptor and confirmed the selectivity pattern in additional cell-based assays. Lall and colleagues (2001) examined ipamorelin’s GH-releasing effects across species, confirming the pulsatile-preserving pattern in additional preclinical models. Together these papers solidified the receptor-binding model that Raun had established functionally a year earlier.
Gobburu and colleagues published a pharmacokinetic-pharmacodynamic analysis of ipamorelin in humans, modeling the GH response time course after intravenous administration. The PK/PD relationship they characterized. short-duration GH elevation following ipamorelin exposure, with return to baseline within a few hours. is the data underlying the commonly cited ~2-hour half-life figure (PMID: 10456220). This paper is one of the few human pharmacokinetic studies in the ipamorelin literature.
The most-cited modern ipamorelin study isn’t a GH study at all. Beck and colleagues conducted a phase 2b randomized controlled trial of ipamorelin in patients with postoperative ileus following bowel resection (PMID: 24506597). The hypothesis was that ghrelin receptor activation would accelerate return of gastrointestinal function. The trial reported modest improvements on some endpoints but did not meet its primary endpoint with statistical significance robust enough to support further development for that indication.
The Beck trial is important to understand because it represents the only large-scale modern human investigation of ipamorelin, and it was conducted for a non-GH indication. The compound has not, as of the 2026 literature, advanced to phase 3 for any indication.
In native GH physiology, two upstream signals converge on the somatotroph to trigger pulsatile GH release: GHRH from the hypothalamus, and ghrelin from the stomach (and centrally). The two signals activate different receptors (GHRH-R and GHSR-1a, respectively) and different intracellular pathways (Gs/cAMP for GHRH-R; Gq/calcium for GHSR-1a), and their combined effect on GH release is more than additive. it’s synergistic. This two-receptor model has been established across multiple preclinical comparison studies.
CJC-1295 is a modified GHRH analog. Ipamorelin is a GHSR-1a agonist. Combining them in a single research preparation lets investigators model the natural two-input convergence pharmacologically. one molecule activating each upstream receptor. The synergy is studied in preclinical models for what it reveals about pituitary signaling integration and pulsatile GH dynamics.
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | Modified GHRH analog | Selective ghrelin receptor agonist (GHRP class) |
| Receptor target | GHRH receptor (GHRH-R) | GHSR-1a (ghrelin receptor) |
| Intracellular pathway | Gs / cAMP / PKA | Gq / PLC / IP3 / calcium |
| Half-life (research models) | ~30 min (no DAC) to 6–10 days (with DAC) | ~2 hours |
| Off-target hormone elevation | Minimal (selective GHRH-R) | Minimal (selective GHSR-1a) |
The GHRP family is a small group of synthetic compounds. GHRP-6, GHRP-2, hexarelin, ipamorelin. all of which activate GHSR-1a and trigger GH release. They differ in potency, selectivity, and structural features. Ipamorelin sits at the high-selectivity, moderate-potency end of the family.
| Compound | GH release magnitude | Cortisol/ACTH elevation | Prolactin elevation |
|---|---|---|---|
| Ipamorelin | Moderate | Minimal | Minimal |
| GHRP-6 | Moderate | Notable | Notable |
| GHRP-2 | High | Moderate | Moderate |
| Hexarelin | High | Substantial | Substantial |
Comparison findings drawn from Raun et al. (1998, PMID: 9849822) and corroborating receptor pharmacology literature. For a deeper comparison of ipamorelin against the alternative GHRH analog Tesamorelin, see the Vitro Research Library comparison guide.
Ipamorelin is supplied as a lyophilized white powder. Lyophilization. essentially freeze-drying under vacuum. is the standard preservation method for small compounds because water is the primary driver of degradation pathways like deamidation and oxidation. In the lyophilized state, ipamorelin is stable at 2–8°C for extended periods and at −20°C for long-term storage, consistent with general handling parameters for small synthetic compounds.
In laboratory protocols, ipamorelin is reconstituted with bacteriostatic water or sterile water for injection, depending on the experimental design and intended duration of use. Bacteriostatic water is preferred when the reconstituted preparation will be used over multiple days, because the benzyl alcohol preservative inhibits microbial growth.
Once reconstituted, ipamorelin solutions are typically stable for 1–4 weeks at 2–8°C, with shorter stability windows at room temperature. Research handling treats reconstituted preparations as having a degradation clock that begins at the moment water is added.
For laboratory research, identity and purity verification is non-trivial. The standard analytical stack is HPLC for purity quantification and mass spectrometry for identity confirmation. Every batch of ipamorelin from Vitro Labs is verified by Freedom Diagnostics, an independent ISO-certified analytical laboratory, with batch-specific Certificates of Analysis documenting identity and purity. See Vitro’s COA documentation for current batch data.
As of the 2026 literature review, no major new ipamorelin-specific clinical trials have been indexed in PubMed since the Beck et al. (2014) postoperative ileus study (PMID: 24506597). The compound’s preclinical pharmacology was largely settled by the Raun, Johansen, Lall, and Gobburu papers published between 1998 and 2001.
The broader ghrelin receptor field continues to develop. including work on ghrelin receptor inverse agonists, biased agonism at GHSR-1a, and the role of the ghrelin system in metabolism and aging. but ipamorelin itself remains primarily a reference compound rather than an active investigational target.
This is meaningful research context. The absence of new trials does not reflect a problem with the compound. it reflects the fact that the original characterization was complete enough that the molecule transitioned from a candidate compound to a research tool. Investigators today use ipamorelin to probe GHSR-1a biology, not to develop ipamorelin itself as a therapeutic.
📋 Quick Reference: Ipamorelin. synthetic 5-amino-acid compound, selective GHSR-1a agonist, ~2-hour half-life in research models, characterized 1998 (Raun et al., PMID: 9849822), most recent major clinical study 2014 (Beck et al., PMID: 24506597). For laboratory research use only. Not for human consumption.
Approximately 2 hours. The pharmacokinetic modeling work by Gobburu et al. (1999) characterized the GH response time course following intravenous administration and supports the commonly cited ~2-hour half-life figure (PMID: 10456220). This short half-life is consistent with ipamorelin’s design as a pulsatile-exposure research compound rather than a sustained-release molecule.
They target different receptors. CJC-1295 is a modified GHRH analog that activates the GHRH receptor on pituitary somatotroph cells via the Gs/cAMP/PKA pathway. Ipamorelin is a selective agonist at the GHSR-1a receptor. the ghrelin receptor. and signals via the Gq/PLC/calcium pathway. The two compounds activate the same downstream effect (GH release) through complementary upstream mechanisms, which is why they are paired in research protocols modeling the two-receptor convergence of native pulsatile GH biology.
In the foundational comparison study by Raun et al. (1998), ipamorelin produced growth hormone release comparable to GHRP-6 in magnitude but with minimal elevation of ACTH, cortisol, and prolactin. the three off-target hormones that the older GHRPs (GHRP-6, hexarelin) elevated substantially (PMID: 9849822). This selectivity profile made ipamorelin a reference compound in GHSR-1a research, where clean signal at one receptor without contamination from the stress-axis or prolactin pathways is methodologically valuable.
The Beck phase 2b trial examined ipamorelin in patients with postoperative ileus following bowel resection (PMID: 24506597). The hypothesis was that ghrelin receptor activation in the gut and brain would accelerate return of gastrointestinal function after surgery. The trial reported modest improvements on some secondary endpoints but did not meet its primary endpoint with statistical significance sufficient to support further clinical development for that indication. It remains the most recent large-scale human study of ipamorelin in the published literature.
Ipamorelin is supplied as a lyophilized white powder. In the lyophilized state it is stable at 2–8°C for extended periods and at −20°C for long-term storage. Reconstitution in research protocols typically uses bacteriostatic water or sterile water for injection. Reconstituted solutions are generally stable for 1–4 weeks at 2–8°C, with degradation accelerating at higher temperatures. Identity and purity verification uses HPLC and mass spectrometry, documented in batch-specific Certificates of Analysis.
No. Ipamorelin is not approved by the FDA or equivalent regulatory authorities for any human or animal therapeutic indication. It is supplied strictly as a research compound for laboratory and in vitro investigation by qualified research customers. All Vitro Labs products are analytical-grade biochemical reference standards intended for in-vitro research, analytical method development, identity verification, and laboratory evaluation. not for human or animal consumption.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. Ipamorelin is a research compound not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
